Pharmacologic and toxicologic studies with the polymyxins. 3. Consideration regarding clinical use in dogs.
D000618:Aminohippuric Acids / Q000378:metabolism; D000818:Animals; D003091:Colistin / Q000009:adverse effects / Q000627:therapeutic use*; D004285:Dogs; D005919:Glomerular Filtration Rate; D005947:Glucose / Q000378:metabolism; D007444:Inulin / Q000378:metabolism; D007668:Kidney / Q000378:metabolism; D007671:Kidney Concentrating Ability / Q000187:drug effects*; D007674:Kidney Diseases / Q000139:chemically induced / Q000378:metabolism; D007684:Kidney Tubules / Q000378:metabolism; D008698:Mesylates / Q000627:therapeutic use; D009566:Nitrates; D011113:Polymyxins / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D013431:Sulfates / Q000627:therapeutic use; D013997:Time Factors
D000618:Aminohippuric Acids; D008698:Mesylates; D009566:Nitrates; D011113:Polymyxins; D013431:Sulfates; D007444:Inulin; D005947:Glucose; D003091:Colistin